Integrity BMS    

Log In

Forgot Your Password?

Not a member? Click here!

New Outcomes Study for Ticagrelor (BRILINTA™) to Examine Longer-term Treatment for Post- ACS Patients
Invited Faculty
TRA 2P-TIMI 50 Trial
Abbott Advances its Revolutionary Fully Bioabsorbable Drug Eluting Stent with Initiation of Next Phase of Clinical Trial
Vascular Solutions Launches the GuideLiner™ Catheter



Changing Paradigm for HF Therapy

The prognosis of many patients with heart failure (HF) remains poor despite optimal medical therapy. A randomized study of the angiotensin receptor-neprilysin inhibitor LCZ696 in patients with class II-IV HF and ejection fraction ≤40% has shown to reduce the risk of death and of hospitalization.

For more, click here




Thrombus Aspiration in STEMI

The clinical benefit of routine thrombus aspiration in patients undergoing PPCI for STEMI is uncertain. A randomized study of 7244 such patients has shown that thrombus aspiration does not reduce the rate of death, re-hospitalization for MI or stent thrombosis at 1-year follow-up.

For more, click here




Lack of Benefit with Ivabradine in Stable CAD

The role of Ivabradine in patients with stable CAD without clinical heart failure is unknown. A randomized study of 19,102 such patients has indicated that in this setting, Ivabradine does not reduce the composite of death from CV causes or non-fatal MI.

For more, click here




FFR Guided PCI in Stable CAD: The New Standard of Care

FFR guided PCI is increasingly being recognized as the standard of care in patients with stable CAD. In a landmark analysis of the FAME 2 studies, a strategy of FFR guided PCI plus optimal medical therapy has been associated with reduced rates of death or MI from 8 days to 2 years compared to optimal medical therapy alone.

For more, click here




No Solid Corornary Benefits with Darapladib Post ACS

Lipoprotein-associated phospholipase A2 (Lp-PLA2) may be involved in atherogenesis through inflammation. Darapladib, an Lp-PLA2 inhibitor, has been shown not to reduce the rates of the composite of death, MI or urgent coronary revascularization post acute coronary syndrome.

For more, click here



Untitled Document
Angio in Patients without Stress Test
- Mouin S. Abdallah, MS, et al.
Complementary role of percutaneous and surgical circulatory support in cardiogenic shock: Introduction and objectives
- Holger Thiele, MD
How to Solve a Bifurcation Puzzle?: Anatomical, Physiological, and Clinical Relevance of Bifurcation Lesions
- Bon-Kwon Woo, MD, PhD
The Heart Team: Challenges and Strategies for Success
- David J. Cohen, MD, MSc
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study: (the cardiac-RESCUE program)
- Sylvain Beurtheret, MD, et al.

Live Case Demonstration from Kusatsu Heart Center
Osamu Hatoh, MD
Treating CTO via Radial?
Richard R. Heuser, MD
Patient Selection for CTO Recanalization: What Are the Appropriate Criteria?
Tarek Helmy, MD
Treating CTOs: Is There Enough Evidence-Based Data or do We Need Further Randomized Clinical Trials?
Gerald S. Werner, MD, PhD
Indication for CTO PCI: Clinical Rationale and Appropriateness
J. Aaron Grantham, MD

 Click here to visit the WEBEX archives

Angiotensin–Neprilysin Inhibition Versus Enalapril in Heart Failure.
J McMurray, et al.
NEJM 2014 Online
Ivabradine in Stable Coronary Artery Disease Without Clinical Heart Failure.
K Fox, et al.
NEJM 2014 Online
Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries.
S Yusuf, et al.
NEJM 2014; 371:818-827
Effect of Self-Monitoring and Medication Self-Titration on Systolic Blood Pressure in Hypertensive Patients at High Risk of Cardiovascular Disease: The TASMIN-SR Randomized Clinical Trial.
R McManus, et al.
JAMA 2014; 312:799-808
Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome: The SOLID-TIMI 52 Randomized Clinical Trial.
M O’Donoghue, et al.
JAMA 2014 Online
Colchicine for Prevention of Postpericardiotomy Syndrome and Postoperative Atrial Fibrillation: The COPPS-2 Randomized Clinical Trial.
M Imazio, et al.
JAMA 2014 Online
Electrocardiographic Changes Improve Risk Prediction in Asymptomatic Persons Age 65 Years or Above Without Cardiovascular Disease.
P Jørgensen, et al.
JACC 2014; 64:898-906
Accuracy of Statin Assignment Using the 2013 AHA/ACC Cholesterol Guideline Versus the 2001 NCEP ATP III Guideline: Correlation With Atherosclerotic Plaque Imaging.
K Johnson & D Dowe
JACC 2014: 64:910-919
Translating Stem Cell Research to Cardiac Disease Therapies: Pitfalls and Prospects for Improvement.
M Rosen, et al.
JACC 2014; 64:922-937
Sex Differences in Long-Term Mortality After Myocardial Infarction. A Systematic Review.
E Bucholz, et al.
Circ 2014; 130:757-767
Inflammation and Neovascularization Intertwined in Atherosclerosis: Imaging of Structural and Molecular Imaging Targets.
U Sadat, et al.
Circ 2014; 130:786-794

Poll Archives

Complex Patients Today and Tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents
Prof. Sigmund Silber, MD
First Report on the Pivotal DESolve Nx trial: 6-month Clinical and Multimodality Imaging Results
Alexandre Abizaid, MD, PhD
One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study
Raul Moreno, MD, et al.
Two-year clinical outcomes in the EVOLVE FHU trial
Ian Meredith, MD, PhD
Stephan Windecker, MD, et al.

Outcomes in More Than 7000 Patients With Diabetes After Implantation of the Resolute Zotarolimus-eluting Stent
Rosli Mohd Ali, MD
Safety update and long-term clinical outcomes from all studies in the RESOLUTE Global Clinical Program
Carlo Di Mario, MD
Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial
Stephan Windecker, MD
Angina Status & TLF Creep: Bioabsorbable Stents (BAS) & Drug-Eluting Stents (DES)
Medtronic, Inc.
Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent
Stephan Windecker, MD
Four-year Outcomes from the Randomized Comparison of a Zotarolimus-eluting and an Everolimus-eluting Stent in the RESOLUTE All Comers Trial
Patrick W Serruys MD, PhD
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Prof. Ran Kornowski, MD
The RESOLUTE Program: today and tomorrow
Sigmund Silber, MD, PhD
RESOLUTE International Trial
F-J. Neumann, MD, et al.
Primary Results Following Percutaneous Coronary Intervention with the 38mm Resolute Zotarolimus-eluting Stent
Shirish Hiremath, MD, et al.
Two Year Outcomes Following Implantation of the Resolute Zotarolimus-eluting Stent in Small (less or equal to 2.5 mm) Vessels
Ronald Caputo, MD

Transluminal’s Velox CD Vascular Closure Device Approved in Europe

Thoratec Begins HeartMate PHP CE Mark Trial

William O’Neill, MD, Performs First Transcatheter Triscuspid Valve Replacement in the United States

Boston Scientific and ASAHI INTECC to Collaborate on Cardiac Intervention Devices

Medicare NCD Expands Access to Abbott’s MitraClip System

Medtronic and ACIST Enter Into Co-Promotion of Next-Generation FFR and IVUS Technologies in the USA

Boston Scientific Receives FDA Approval for REBEL Platinum Chromium Coronary Stent System

CE Mark Approved for Boston Scientific’s Agent PTCA Balloon

Siemens to Sell Hospital Information Systems Business to Cerner

St. Jude Medical’s CardioMems HF System Receives CMS Approval for New Technology Add-On Payment

Avinger Begins VISION Trial of the Pantheris Catheter

Enrollment Completed in Pivotal ROADSTER Trial for Silk Road’s Enroute CAS Device

BIOLUX 4EVER Will Evaluate Combined Treatment With Biotronik’s Pulsar-18 Stent and Passeo-18 Lux Balloon for SFA Disease

Teleflex’s Arrow-Clark VectorFlow Chronic Hemodialysis Catheter Receives FDA Clearance

Biotronik Completes Enrollment in SFA Arm of the BIOFLEX-I Study

Boston Scientific Launches Polaris Imaging System

FDA Approves Boston Scientific’s Bare-Metal Rebel PtCr Coronary Stent System

Boston Scientific Launches POLARIS™ Imaging System
Angiomyogenesis & Cell Therapy
Carotid Interventions

Home | CRT2013 | CardioTube | Interesting Cases | Trials | Weekly Poll Archive | Newsletter Archive | Login

Copyright © 2014, CRTONLINE - About / Contact Us. All rights reserved. Privacy Policy
Powered by Multiweb